RESUMEN
INTRODUCTION: Patients with CIDP respond adequately to steroid therapy and intravenous immunoglobulin (IVIG). However, few patients have access to IVIG in developing countries. Little information exists about the clinical response to steroid therapy in Latin American countries. OBJECTIVE: to describe the long-term functional clinical response (24 months) to prednisone therapy in CIDP patients. MATERIAL AND METHODS: A retrospective cohort was conducted. Selection included patients with definitive CIDP diagnosis according to European criteria from the Neuromuscular Diseases clinic of the National Institute of Neurology and Neurosurgery between January 2016 and December 2020. Good response to steroid therapy was defined as with improvement in at least one point on the GBS disability score. Poor response to steroid therapy was defined as patients who did not show improvement in at least one point on the GBS disability score. Patients were evaluated at 3, 6, 12, 18 and 24 months. RESULTS: Forty-seven patients with CIDP were included. Half of them were male and mean age was 46±15 years. Mean time since symptom onset to diagnosis was 6 (IQR 2-12) months. The most common clinical variant was sensory-motor 57.4%, followed by acute-onset CIDP 21.3% and atypical variants 21.2%. At diagnosis our patients presented: mean GBS disability score of 3 (2.25-4) points, MRC score 39.5 ± 12 points, independent gait in 17%, mean prednisone dose of 50 mg (32.5-50). Twenty-four months after prednisone therapy, a less mean GBS disability score -1(0-2) points-, mean MRC score 56.3 ± 5.1 points, independent gait 93% and prednisone dose 1 (0-5) mg. Patients with poor three-month functional clinical response had a delay in diagnosis > 6 months (64.7% vs 27.5%) and atypical clinical variants (47% vs 6.8%). CONCLUSION: CIDP patients treated with prednisone have good long-term functional clinical response. Delay in diagnosis and atypical variant are common clinical characteristics for poor functional clinical response in treatment with prednisone.
TITLE: Eficacia del uso de prednisona como terapia a largo plazo en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC): una cohorte retrospectiva.Introducción. Los pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) responden adecuadamente a la terapia con esteroides y a la inmunoglobulina intravenosa (IgIV). Sin embargo, pocos pacientes tienen acceso a la IgIV en los países en desarrollo. Existe poca información sobre la respuesta clínica a la terapia con esteroides en los países de Latinoamérica. Objetivo. Describir la respuesta clínica funcional a largo plazo (24 meses) a la terapia con prednisona en pacientes con PDIC. Material y métodos. Se realizó una cohorte retrospectiva. La selección incluyó a pacientes con diagnóstico definitivo de PDIC según los criterios europeos de la Clínica de Enfermedades Neuromusculares del Instituto Nacional de Neurología y Neurocirugía entre enero de 2016 y diciembre de 2020. La buena respuesta a la terapia con esteroides se definió como una mejoría al menos en un punto de la Guillain-Barre Disability Score (GBS). La mala respuesta a la terapia con esteroides se definió como pacientes que no mostraron mejoría al menos en un punto en la GBS. Los pacientes fueron evaluados a los 3, 6, 12, 18 y 24 meses. Resultados. Se incluyó a 47 pacientes con PDIC. La mitad de ellos eran varones y la edad media fue de 46 ± 15 años. El tiempo medio desde el inicio de los síntomas hasta el diagnóstico fue de 6 (rango intercuartílico: 2-12) meses. La variante clínica más común fue la sensomotora (57,4%), seguida de la PDIC de inicio agudo (21,3%) y de variantes atípicas (21,2%). En el momento del diagnóstico, nuestros pacientes presentaban: GBS media de 3 (2,25-4) puntos, puntuación de la escala del Medical Research Council (MRC) de 39,5 ± 12 puntos, marcha independiente en el 17% y dosis media de prednisona de 50 mg (32,5-50). Veinticuatro meses después de la terapia con prednisona, la GBS media era menor 1 (0-2) puntos, la puntuación media del MRC era de 56,3 ± 5,1 puntos, había marcha independiente en el 93% y la dosis de prednisona era de 1 mg (0-5). Los pacientes con mala respuesta clínica funcional a los tres meses tuvieron un retraso en el diagnóstico > 6 meses (64,7% frente a 27,5%) y variantes clínicas atípicas (47% frente a 6,8%). Conclusión. Los pacientes con PDIC tratados con prednisona tienen una buena respuesta clínica funcional a largo plazo. El retraso en el diagnóstico y la variante atípica son características clínicas frecuentes de la respuesta clínica funcional deficiente en el tratamiento con prednisona.
Asunto(s)
Glucocorticoides/uso terapéutico , Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante/tratamiento farmacológico , Prednisona/uso terapéutico , Adulto , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Tiempo , Resultado del TratamientoRESUMEN
Introducción: Los pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) responden adecuadamente a la terapia con esteroides y a la inmunoglobulina intravenosa (IgIV). Sin embargo, pocos pacientes tienen acceso a la IgIV en los países en desarrollo. Existe poca información sobre la respuesta clínica a la terapia con esteroides en los países de Latinoamérica. Objetivo: Describir la respuesta clínica funcional a largo plazo (24 meses) a la terapia con prednisona en pacientes con PDIC. Material y métodos. Se realizó una cohorte retrospectiva. La selección incluyó a pacientes con diagnóstico definitivo de PDIC según los criterios europeos de la Clínica de Enfermedades Neuromusculares del Instituto Nacional de Neurología y Neurocirugía entre enero de 2016 y diciembre de 2020. La buena respuesta a la terapia con esteroides se definió como una mejoría al menos en un punto de la Guillain-Barre Disability Score (GBS). La mala respuesta a la terapia con esteroides se definió como pacientes que no mostraron mejoría al menos en un punto en la GBS. Los pacientes fueron evaluados a los 3, 6, 12, 18 y 24 meses. Resultados: Se incluyó a 47 pacientes con PDIC. La mitad de ellos eran varones y la edad media fue de 46 ± 15 años. El tiempo medio desde el inicio de los síntomas hasta el diagnóstico fue de 6 (rango intercuartílico: 2-12) meses. La variante clínica más común fue la sensomotora (57,4%), seguida de la PDIC de inicio agudo (21,3%) y de variantes atípicas (21,2%). En el momento del diagnóstico, nuestros pacientes presentaban: GBS media de 3 (2,25-4) puntos, puntuación de la escala del Medical Research Council (MRC) de 39,5 ± 12 puntos, marcha independiente en el 17% y dosis media de prednisona de 50 mg (32,5-50). Veinticuatro meses después de la terapia con prednisona, la GBS media era menor 1 (0-2) puntos, la puntuación media del MRC era de 56,3 ± 5,1 puntos, había marcha independiente en el 93% y la dosis de prednisona era de 1 mg (0-5)...(AU)
Introduction: Patients with CIDP respond adequately to steroid therapy and intravenous immunoglobulin (IVIG). However, few patients have access to IVIG in developing countries. Little information exists about the clinical response to steroid therapy in Latin American countries. Objective: to describe the long-term functional clinical response (24 months) to prednisone therapy in CIDP patients. Material and methods. A retrospective cohort was conducted. Selection included patients with definitive CIDP diagnosis according to European criteria from the Neuromuscular Diseases clinic of the National Institute of Neurology and Neurosurgery between January 2016 and December 2020. Good response to steroid therapy was defined as with improvement in at least one point on the GBS disability score. Poor response to steroid therapy was defined as patients who did not show improvement in at least one point on the GBS disability score. Patients were evaluated at 3, 6, 12, 18 and 24 months. Results: Forty-seven patients with CIDP were included. Half of them were male and mean age was 46±15 years. Mean time since symptom onset to diagnosis was 6 (IQR 2-12) months. The most common clinical variant was sensory-motor 57.4%, followed by acute-onset CIDP 21.3% and atypical variants 21.2%. At diagnosis our patients presented: mean GBS disability score of 3 (2.25-4) points, MRC score 39.5 ± 12 points, independent gait in 17%, mean prednisone dose of 50 mg (32.5-50). Twenty-four months after prednisone therapy, a less mean GBS disability score 1(0-2) points, mean MRC score 56.3 ± 5.1 points, independent gait 93% and prednisone dose 1 (0-5) mg. Patients with poor three-month functional clinical response had a delay in diagnosis > 6 months (64.7% vs 27.5%) and atypical clinical variants (47% vs 6.8%)...(AU)
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Prednisona/uso terapéutico , Síndrome de Guillain-Barré/tratamiento farmacológico , Pronóstico , Nervios Periféricos , Resultado del Tratamiento , Neurología , Enfermedades del Sistema Nervioso , Estudios de Cohortes , Estudios RetrospectivosRESUMEN
Extramedullary relapse (EMR) represents a poor prognostic marker in the course of multiple myeloma (MM). We reviewed data from 329 patients, diagnosed between 2000 and 2010, without extramedullary disease at onset to explore possible risk factors for EMR. The median overall survival of our study cohort was 6.4 years. The risk of EMR was 28 % with a median time from diagnosis to first EMR of 2.2 years (0.2-9.1 years). Patients with soft tissue masses located in extra-osseous organs (EMR-S) showed the worst outcome, compared to those with tumor masses arising from adjacent bone (EMR-B) (median OS 1.6 vs 2.4 years, p = 0.006). In addition, patients with EMR-S showed a significant trend for further development of extramedullary masses in a very short time (3.7 vs 5.7 months for EMR-B, p = 0.043). Multivariate analysis failed to identify any clinically presenting features predictive for EMR. The occurrence of EMR was higher in patients with more complex treatment history, defined on the basis of longer treatment duration (≥6 vs <6 months) and on elevated number of treatment lines administered (>2 vs ≤2 lines) (HR = 4.5, p < 0.001 and HR = 9.0, p < 0.001, respectively, when one or both factors are present).In conclusion, increasing burden of treatment might be a possible risk factor for EMR. MM patients with multiple relapses should be comprehensively investigated including, when possible, a whole-body-targeted radiologic technique to accurately detect EMR. Treatment choice should take into account the very poor outcome for patients with soft tissue involvement.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Mieloma Múltiple/tratamiento farmacológico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Sarcoma Mieloide/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Bortezomib/administración & dosificación , Femenino , Estudios de Seguimiento , Humanos , Lenalidomida , Masculino , Persona de Mediana Edad , Mieloma Múltiple/diagnóstico , Mieloma Múltiple/mortalidad , Recurrencia Local de Neoplasia/diagnóstico , Recurrencia Local de Neoplasia/mortalidad , Estudios Retrospectivos , Factores de Riesgo , Sarcoma Mieloide/diagnóstico , Sarcoma Mieloide/mortalidad , Tasa de Supervivencia/tendencias , Talidomida/administración & dosificación , Talidomida/análogos & derivadosRESUMEN
Recent reports identify the ratio between absolute neutrophil count (ANC) and absolute lymphocyte count (ALC), called neutrophil to lymphocyte ratio (NLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. We retrospectively examined the NLR in a cohort of 309 newly diagnosed multiple myeloma (MM) patients treated upfront with novel agents. NLR was calculated using data obtained from the complete blood count (CBC) at diagnosis and subsequently correlated with PFS and OS. The median NLR was 1.9 (range 0.4-15.9). Higher NLR was independent of international staging system (ISS) stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2 and 36.4 % for patients with NLR ≥ 2 versus 25.5 and 66.6 % in patients with NLR < 2. Among younger patients (age <65 years, N = 179), NLR ≥ 2 had a negative prognostic impact on both PFS and OS, in all ISS stages. By combining ISS stage and NLR in a model limited to young patients, we found that 19 % of the patients were classified as very low risk, 70 % standard risk and 11 % very high risk. The 5-year estimates were 39.3, 19.4 and 10.9 % for PFS and 95.8, 50.9 and 23.6 % for OS for very low, standard-risk and very high-risk groups. We found NLR to be a predictor of PFS and OS in MM patients treated upfront with novel agents. NLR can be combined with ISS staging system to identify patients with dismal outcome. However, larger cohorts and prospective studies are needed to use NLR as additional parameter to personalise MM therapy in the era of novel agents.
Asunto(s)
Drogas en Investigación/administración & dosificación , Quimioterapia de Inducción , Linfocitos/patología , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/patología , Neutrófilos/patología , Adulto , Anciano , Anciano de 80 o más Años , Recuento de Células Sanguíneas , Femenino , Humanos , Quimioterapia de Inducción/métodos , Lenalidomida , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/sangre , Terapia Neoadyuvante , Estadificación de Neoplasias , Estudios Retrospectivos , Medición de Riesgo , Talidomida/administración & dosificación , Talidomida/análogos & derivadosRESUMEN
Breast milk is the most effective strategy to protect infants against necrotizing enterocolitis (NEC), a devastating disease that is characterized by severe intestinal necrosis. Previous studies have demonstrated that the lipopolysaccharide receptor Toll-like receptor 4 (TLR4) plays a critical role in NEC development via deleterious effects on mucosal injury and repair. We now hypothesize that breast milk protects against NEC by inhibiting TLR4 within the intestinal epithelium, and sought to determine the mechanisms involved. Breast milk protected against NEC and reduced TLR4 signaling in wild-type neonatal mice, but not in mice lacking the epidermal growth factor receptor (EGFR), whereas selective removal of EGF from breast milk reduced its protective properties, indicating that breast milk inhibits NEC and attenuates TLR4 signaling via EGF/EGFR activation. Overexpression of TLR4 in the intestinal epithelium reversed the protective effects of breast milk. The protective effects of breast milk occurred via inhibition of enterocyte apoptosis and restoration of enterocyte proliferation. Importantly, in IEC-6 enterocytes, breast milk inhibited TLR4 signaling via inhibition of glycogen synthase kinase-3ß (GSK3ß). Taken together, these findings offer mechanistic insights into the protective role for breast milk in NEC, and support a link between growth factor and innate immune receptors in NEC pathogenesis.
Asunto(s)
Apoptosis/inmunología , Enterocolitis Necrotizante/prevención & control , Enterocitos/inmunología , Leche/inmunología , Transducción de Señal/inmunología , Receptor Toll-Like 4/inmunología , Animales , Apoptosis/genética , Línea Celular , Enterocolitis Necrotizante/genética , Enterocolitis Necrotizante/inmunología , Enterocolitis Necrotizante/patología , Enterocitos/patología , Factor de Crecimiento Epidérmico/genética , Factor de Crecimiento Epidérmico/inmunología , Receptores ErbB/genética , Receptores ErbB/inmunología , Femenino , Glucógeno Sintasa Quinasa 3/genética , Glucógeno Sintasa Quinasa 3/inmunología , Glucógeno Sintasa Quinasa 3 beta , Ratones , Transducción de Señal/genética , Receptor Toll-Like 4/genéticaRESUMEN
BACKGROUND: Pain is a frequent and disabling symptom in multiple sclerosis (MS) patients. In this study we assess the frequency and intensity of pain, as well as its impact on the quality of life and activities of daily living, in a sample of MS patients. METHODS: One hundred and twenty eight MS patients underwent a neurological examination, a structured interview designed to assess pain, and a Medical Outcome 36-item Short Form Health Survey. Functional status was assessed by means of the Barthel Index (BI) and Rivermead Mobility Index. We also assessed the presence of depression, by means of the Montgomery and Asberg Depression Rating Scale, and fatigue, by means of the Fatigue Severity Scale. An algometer was used to measure thermal and discomfort thresholds in all of the patients and a group of 61 age- and sex-matched healthy subjects. RESULTS: Pain was present in 61 patients. No differences were found between patients with and those without pain in disease duration, disease form or Expanded Disability Status Scale and its functional systems. Patients with pain had a lower vitality score (p = 0.008), mental health score (p = 0.03) and physical (p < 0.001) and mental composite scores (p = 0.01) than patients without pain. Furthermore, there was a significant difference between patients with and those without pain in the BI (p = 0.04). Both thermal and discomfort thresholds, as assessed by means of the algometer, were statistically lower in MS patients than in controls, whereas no difference was observed between patients with and those without pain. There was a statistically significant improvement in the thermal threshold in patients with pain who were treated pharmacologically when compared with those who were not treated (p = 0.049). CONCLUSION: The results of this study provide further evidence of the negative impact that the presence of pain has on both the quality of life and activities of daily living in MS patients. The lower thermal and discomfort thresholds observed in our MS patients, compared with controls, may represent a predisposition to develop pain during the course of the disease.
Asunto(s)
Esclerosis Múltiple/complicaciones , Dimensión del Dolor , Umbral del Dolor , Dolor/diagnóstico , Dolor/etiología , Actividades Cotidianas , Adulto , Anciano , Enfermedad Crónica , Evaluación de la Discapacidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/psicología , Dolor/psicología , Calidad de VidaRESUMEN
Angiomyolipoma has a unique immunophenotype with co-expression of muscle-specific actin and melanocytic markers such as HMB-45 and Melan-A. The most recently developed melanocytic markers, microphthalmia transcription factor and tyrosinase, have not been studied in the diagnosis of angiomyolipoma. We tested 29 renal angiomyolipomas (21 classic histology, 4 epithelioid variants, 2 lipomatous variants, and 2 leiomyomatous variants) with an immunohistochemical panel, including microphthalmia transcription factor, tyrosinase, HMB-45, Melan-A, and muscle-specific actin. Results were compared with 15 renal cell carcinomas (9 conventional types, 6 with sarcomatoid change), 2 leiomyosarcomas, 5 liposarcomas, and 1 unclassified high-grade sarcoma. Microphthalmia transcription factor expression was seen in 22 of 29 angiomyolipomas, one renal cell carcinoma, and one well-differentiated liposarcoma (that is, 2 of 23 non-angiomyolipomas; sensitivity 75%, specificity 91%). Tyrosinase expression was seen in 4 of 29 angiomyolipomas and 0 of 23 non-angiomyolipomas (sensitivity 14%, specificity 100%). HMB-45 was positive in 24 of 29 angiomyolipomas and 0 of 23 non-angiomyolipomas (sensitivity 83%, specificity 100%). Melan-A was expressed by 25 of 29 angiomyolipomas and 0 of 23 non-angiomyolipomas (sensitivity 86%, specificity 100%). Muscle-specific actin was expressed by 29 of 29 angiomyolipomas and 2 of 23 non-angiomyolipomas (both leiomyosarcomas; sensitivity 100%, specificity 91% [100% excluding leiomyosarcomas]). Microphthalmia transcription factor showed the most widespread staining in angiomyolipoma (50% of cases staining more than half of the tumor cells) followed by Melan-A (24% of cases staining more than 50%). Only three cases showed positivity for all four melanocytic markers, while in one case each only microphthalmia transcription factor and Melan-A were positive. We conclude that microphthalmia transcription factor, but not tyrosinase immunostaining, has a sensitivity and specificity that rivals those of the established markers, HMB-45 and Melan-A, in the diagnosis of angiomyolipoma. Our data supports the use of a panel in difficult cases that includes antibodies to microphthalmia transcription factor, either Melan-A or HMB-45, and muscle-specific actin to provide the best mix of high sensitivity, high specificity, nuclear and cytoplasmic immunolocalization, and widespread staining of cells within a given tumor.
Asunto(s)
Angiomiolipoma/química , Biomarcadores de Tumor/análisis , Proteínas de Unión al ADN/análisis , Neoplasias Renales/química , Monofenol Monooxigenasa/análisis , Proteínas de Neoplasias/análisis , Factores de Transcripción , Actinas/análisis , Antígenos de Neoplasias , Humanos , Inmunohistoquímica , Antígenos Específicos del Melanoma , Factor de Transcripción Asociado a Microftalmía , Sensibilidad y EspecificidadRESUMEN
The aim of this study was to assess the relationship of immunoreactivity of cytokeratin 20 (CK20) and CD44 across the spectrum of urothelial neoplasia using the WHO/ISUP consensus classification. A total of 120 papillary urothelial pTa and pT1 tumors (8 papillomas, 8 neoplasms of low malignant potential, and 42 low-grade and 62 high-grade carcinomas) were immunostained by using CK20 and CD44 antibodies. The relationships of tumor grade, pathologic stage, recurrences, and progression in stage with CK20 and CD44 immunoreactivity were assessed. WHO/ISUP grade correlated with tumor stage (P < 0.005), recurrence (P = 0.02), and progression in stage (P = 0.031). Normal urothelium showed CK20 immunoreactivity restricted to a few umbrella cells. Expression of CD44 in normal urothelium was restricted to the basal cell layer. Loss of CD44 immunoreactivity and increasing CK20 positivity were significantly associated with increasing tumor grade and stage (P < 0.005). An inverse relationship was observed in the staining patterns of CK20 and CD44 within individual cases, as well as in the aggregate data, with 79.2% of tumors with CD44 loss showing CK20 positivity (P < 0.001). In conclusion, CK20 and CD44 immunoreactivity are significantly related to the WHO/ISUP grade and to each other, and our data suggest their potential combined utility in predicting biologic behavior in patients with papillary urothelial pTa and pT1 neoplasms.
Asunto(s)
Carcinoma Papilar/metabolismo , Receptores de Hialuranos/metabolismo , Proteínas de Filamentos Intermediarios/metabolismo , Papiloma/metabolismo , Neoplasias de la Vejiga Urinaria/metabolismo , Adulto , Anciano , Carcinoma Papilar/patología , Femenino , Humanos , Cooperación Internacional , Queratina-20 , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Estadificación de Neoplasias , Papiloma/patología , Sociedades Médicas , Neoplasias de la Vejiga Urinaria/patología , Urología , Urotelio/patología , Organización Mundial de la SaludAsunto(s)
Lupus Eritematoso Sistémico/sangre , Prolactina/sangre , Adulto , Autoantígenos/análisis , Femenino , Humanos , Hiperprolactinemia/sangre , Hiperprolactinemia/etiología , Lupus Eritematoso Sistémico/inmunología , Lupus Eritematoso Sistémico/fisiopatología , Persona de Mediana Edad , Valores de ReferenciaRESUMEN
In this paper, we review some past and present trends in biodiversity conservation in Mexico and explore possible explanations of why, in spite of this long history of depredation and ineffective conservation policies, the ecosystems have been able to cope with and retain most of their biological components. We suggest a hypothesis based on the persistence of a complex mosaic of past and present traditional land uses as a possible explanation for this resilience. We propose an agenda for the scope of future conservation research and policy, particularly the need to take the socioeconomic context of environmental degradation into account. We put forth a series of questions that we think need to be investigated if the conservation research community is to participate in developing solutions for the future welfare of the human species and of biodiversity on earth.
Asunto(s)
Agricultura/métodos , Conservación de los Recursos Naturales/métodos , Abastecimiento de Alimentos , Crecimiento Demográfico , Agricultura/tendencias , Animales , Conservación de los Recursos Naturales/tendencias , Humanos , MéxicoRESUMEN
Primary pigmented nodular adrenocortical disease is a rare cause of Cushing's syndrome in children and young adults. It is characterized by hypercorticolism resistant to dexamethasone suppression and at microscopic examination by multiple small black cortical nodules containing large cells with eosinophilic cytoplasm and lipofuscin with internodular cortical atrophy. Its pathogenesis is unknown. Bilateral adrenalectomy is the treatment of choice. We report a case of Cushing's syndrome due to primary pigmented nodular adrenocortical disease in a 32 year old female and review the literature.
Asunto(s)
Enfermedades de la Corteza Suprarrenal/complicaciones , Síndrome de Cushing/etiología , Enfermedades de la Corteza Suprarrenal/metabolismo , Adulto , Síndrome de Cushing/metabolismo , Femenino , Humanos , Hidrocortisona/metabolismoRESUMEN
The histomorphologic features, immunohistochemical reactivity, and DNA content of four cases of a rare tubular variant of seminoma are presented. These neoplasms were characterized by a predominantly tubular architectural pattern that resembled yolk sac tumor, embryonal carcinoma, and sex cord-stromal tumors. The patients' ages were 15, 24, 27, and 44 years. On initial examination, three patients had painless testicular enlargement, and one had a large retroperitoneal mass and a clinically occult primary testicular tumor. The size of the tumors ranged from 1.7 to 6.0 (mean, 4.0) cm. Microscopically, the tumor cells had a tubular or tubulopapillary pattern that consisted of a single layer of cells, often in a back-to-back arrangement with intervening fibrovascular septa. Areas of classic seminoma were present in all cases. Scattered syncytiotrophoblastic giant cells were seen in two tumors. The tumor cells of both the classic and the tubular components of the seminomas were diffusely positive for placental alkaline phosphatase but were negative for cytokeratin and alpha-fetoprotein. DNA flow-cytometric analysis demonstrated abnormal stemlines with hypotetraploid DNA and a mean DNA index of 1.7 in both the classic and the tubular components. The presence of concurrent areas of classic seminoma, similar cytologic features in the tubular and classic seminoma areas, and the identical immunohistochemical and DNA flow-cytometric findings indicate that tubular seminoma is a histologic variant of seminoma. Although the behavior of the tubular variant appeared not to differ from that of classic seminoma in our small series, its recognition is important in the differential diagnosis and management of testicular masses.
Asunto(s)
ADN de Neoplasias/análisis , Seminoma/genética , Seminoma/patología , Neoplasias Testiculares/genética , Neoplasias Testiculares/patología , Adolescente , Adulto , Citometría de Flujo , Humanos , Inmunohistoquímica/métodos , Masculino , Coloración y EtiquetadoRESUMEN
We report a study of seven men, aged 16 to 76 years (average age, 47.4 years) with granulosa cell tumor (GCT) of the testis. Three patients presented with testicular enlargement of several years' duration and a fourth presented with a testicular enlargement of unknown duration. The tumors in three patients were detected during routine physical examination. None of the patients had endocrine-related symptoms. All tumors were well circumscribed and showed the solid, cystic, microfollicular, gyriform, insular, and trabecular patterns typical of GCT of the ovary. Call-Exner bodies were present in three tumors and two tumors had a focal spindle-cell component. In one case the surrounding testicular parenchyma showed Leydig's cell hyperplasia and a Sertoli cell nodule. The tumor cells revealed strong immunoreactivity for vimentin but showed no expression for keratin or epithelial membrane antigen. One patient developed liver and retroperitoneal lymph node metastases 121 months after initial diagnosis and died 13 months later. Another patient initially presented with retroperitoneal lymph node metastasis and developed metastasis to the inguinal lymph nodes 12 months later. Three patients are alive at 1, 4, and 37 months with no evidence of disease. Another patient died of an unrelated condition. Follow-up information was not available for the seventh patient. Twelve cases of GCT of the adult testis have been reported in the literature, with metastases occurring in two: one of these two patients had a tumor for 8 years and died of disease 5 months after diagnosis with multiple metastases and the other had metastasis at the time of diagnosis, but was free of disease for 14 years. Our findings and a review of the literature indicate that GCT of the adult testis is a rare and slow-growing neoplasm with the potential to form distant metastases. Because recurrence or distant metastasis may occur late in the clinical course, long-term follow-up of these patients is recommended.
Asunto(s)
Tumor de Células de la Granulosa/patología , Neoplasias Testiculares/patología , Adolescente , Adulto , Anciano , Tumor de Células de la Granulosa/química , Humanos , Metástasis Linfática , Masculino , Persona de Mediana Edad , Neoplasias Testiculares/química , Factores de Tiempo , Vimentina/análisisRESUMEN
The cases of three patients with primary carcinoid tumor of the testis were reported. The patients were 41, 44, and 83 years of age. At initial examination, all three had testicular masses with or without associated pain, and none had the carcinoid syndrome. The tumors measured 4.3 cm, 3.0 cm, and 6.5 cm in dimension. All three tumors manifested classic histologic features of carcinoid tumors. The neoplastic cells exhibited argyrophilia, and all were immunoreactive to chromogranin, serotonin, neuron-specific enolase, and cytokeratin. Two tumors had positive test results for gastrin and one had positive test results for substance P and vasoactive intestinal polypeptide. No tumors reacted with somatostatin, insulin, pancreatic polypeptide, or placental alkaline phosphatase. Intracytoplasmic, membrane-bound, round-to-elliptical pleomorphic granules were identified by ultrastructural analysis in all cases. DNA flow cytometric analysis revealed a low degree (near-diploid) DNA aneuploidy in all cases, with a DNA index of 1.15 in two tumors and 1.3 in the third tumor. The three patients are alive and well 11 years, 7 years, and 6 months, respectively, after diagnosis. A total of 57 cases of this entity, including the 3 reported here, have been reported. Of these, 43 were pure carcinoid, and 14 were associated with teratoma; 6 (11.6%) patients developed metastases. Tumor size and the presence of carcinoid syndrome have been found to correlate with metastatic potential. Neither tumor necrosis nor local tumor invasion (into vessels, tunica albuginea, etc.) correlated with adverse prognosis. Carcinoid tumor of the testis is a rare indolent neoplasm with potential for distant metastases.